Viking Closes $575M Upsized Offering After Full Underwriter Option Exercise
VKTX sits 33% above its 52-week low of $24.88 on elevated volume (2.3× avg).
Summary
Viking Therapeutics closed its concurrent common stock and convertible notes offerings, raising approximately $575 million in gross proceeds after underwriters fully exercised their options. The final terms include 9.04 million shares at $35.00 and $258.75 million of 2.00% convertible notes due 2032, with net proceeds of about $547.8 million. This follows the upsized pricing announced on September 24 and final prospectus supplements filed September 25. The capital strengthens the balance sheet for advancing VK2735 and VK3019 clinical programs. The full exercise of options signals strong demand, but the dilution and conversion overhang are now fully priced in.
Updates
· SEC 8-K — Net proceeds were approximately $297.0 million from the equity offering and $250.8 million from the debt offering, totaling about $547.8 million.
At the time of this announcement, VKTX was trading at $33.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $24.88 to $43.15. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.